Expert insight into the data presented at ESMO 2023 on the EV-302 study of enfortumab vedotin and pembrolizumab in the management of locally advanced or metastatic urothelial carcinoma.
This is a video synopsis/summary of a panel discussion involving Sia Daneshmand, MD.
Daneshmand discusses results from the EV-302 phase 3 trial of enfortumab vedotin (EV) plus pembrolizumab (pembro) vs chemotherapy for first-line treatment of locally advanced or metastatic urothelial carcinoma. He notes that 10% to 20% of patients with bladder cancer present with metastatic disease, with up to 50% progressing post cystectomy. Cisplatin-based chemotherapy has been considered the standard of care for decades.
The EV-302 trial compared EV-pembro with chemotherapy (gemcitabine with cisplatin or carboplatin) in 886 patients. With median 17.2-month follow-up, EV-pembro significantly prolonged progression-free survival (12.5 vs 6.3 months; HR, 0.45) and overall survival (31.5 vs 16.1 months; HR, 0.47), reducing the risk of progression or death by 55% and 53%, respectively. Approximately one-third of patients had a prolonged response to EV-pembro.
Daneshmand believes these results are strong enough to change the standard of care for first-line treatment of advanced urothelial carcinoma to EV-pembro for both cisplatin-eligible and -ineligible patients. He expects rapid adoption of guidelines given the magnitude of benefit demonstrated.
Video synopsis is AI-generated and reviewed by AJMCÒ editorial staff.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More